In-vitro Inflammatory Bowel Disease Diagnostic Market: Introduction
According to the report, the global in-vitro inflammatory bowel disease diagnostic market was valued at US$ 1.5 Bn in 2019. It is projected to expand at a CAGR of ~4% from 2024 to 2030. Inflammatory bowel disease (IBD) is a terms used to describe disorders that involve chronic inflammation of the digestive tract. Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn’s disease. Assays/biomarkers and analyzers are used to diagnose in-vitro inflammatory bowel disease.
The rise in prevalence of inflammatory bowel disease and an increase in the demand for less-invasive, resource-benefit boost the global in-vitro inflammatory bowel disease diagnostic market. North America dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is anticipated to continue during the forecast period. High prevalence of diseases and well-established healthcare infrastructure enable proper diagnosis of IBD are responsible for high market share of the region.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74162
Asia Pacific is expected to be a highly lucrative market for in-vitro inflammatory bowel disease diagnostic during the forecast period. Majority of countries in Asia Pacific are economically developing and numerous players are making significant investment in the region. These factors boost the market in Asia Pacific. The rise in technological advancements in countries in terms of healthcare and medical research is anticipated to fuel the market in the region.
High Prevalence of Inflammatory Bowel Disease (IBD) and Newer Biomarkers Offer Significant Opportunities
According to IBD Support Australia Incorporated, in 2015, around 61,000 people in Australia are affected by inflammatory bowel disease of which, around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis. Furthermore, according to New Zealand Ministry of Health more than 15,000 people are affected by IBD in New Zealand. New Zealand and Australia have a high prevalence of IBD in the world. Thus, rising cases of inflammatory bowel diseases boost the global market.
Major innovations in diagnostic technologies include the development of more sophisticated endoscopic and noninvasive techniques to improve the identification of complications, in particular, in malignant diseases associated with IBD. The future would see further progress in the identification of genetic susceptibility factors and of protein biomarkers and their use to describe the molecular epidemiology of IBD. It is expected that future diagnostics would include molecular parameters to detect early disease or guide therapies by predicting the individual course of disease.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=74162
In November 2016, Inova Diagnostics, announced the U.S Food and Drug Administration (FDA) clearance of QUANTA Lite Calprotectin Extended Range, an assay which aids in the diagnosis of Inflammatory Bowel Disease (IBD) and can help differentiate IBD from Irritable Bowel Syndrome (IBS).
Assays/Biomarker to Dominate Market
In terms of product, the global in-vitro inflammatory bowel disease diagnostic market has been divided into assays/biomarker and analyzers. The assays/biomarker segment has been further subdivided into calprotectin, lactoferrin, bile acids, H. pylori SA, pancreatic elastase, and others. The assays/biomarker segment dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is likely to continue during the forecast period, owing to an increase in cases of nerve pain and launch of new products.
In June 2019, Bühlmann Laboratories received 510(k) clearance from the U.S. Food and Drug Administration for its fCal Turbo calprotectin test, which is an immuno turbidimetric fecal calprotectin assay. fCAL turbo assay represents a high-throughput option to the company’s recently FDA-cleared fCal ELISA assay.
Request for Analysis of COVID-19 Impact on In-vitro Inflammatory Bowel Disease Diagnostic Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74162
Hospitals to be Promising End User
Based on end user, the global in-vitro inflammatory bowel disease diagnostic market has been classified into diagnostic laboratories, hospitals, and research institutes. The hospitals segment is expected to expand at a notable CAGR during the forecast period. The expansion of the segment can be attributed to a rise in the rate of hospitalization for inflammatory bowel diseases and a wide range of services offered by hospitals at a single site.
North America to Dominate Global Market
The global in-vitro inflammatory bowel disease diagnostic market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2019, followed by Europe. North America accounted for a major share of the global in-vitro inflammatory bowel disease diagnostic market in 2019, owing to rise in the rate of adoption of new technology for detection of diseases and an increase in the number of various disorders. The in-vitro inflammatory bowel disease diagnostic market in Asia Pacific is anticipated to expand at a higher CAGR from 2024 to 2030. The expansion of the in-vitro inflammatory bowel disease diagnostic market in the region can be attributed to a rise in prevalence of disorders and an increase in awareness about diagnosis in the region.
Buy In-vitro Inflammatory Bowel Disease Diagnostic Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=74162<ype=S
DiaSorin S.p.A, BÜHLMANN Laboratories AG, and F. Hoffmann-La Roche AG are leading players operating in the global in-vitro inflammatory bowel disease diagnostic market and hold majority market share. The global in-vitro inflammatory bowel disease diagnostic market is fragmented in terms of number of players. Key players in the global market include DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott, Quidel Corporation, American Laboratory Products Company (ALPCO), Certest Biotec SL., and Biosystems S.A. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to operate their business in the global in-vitro inflammatory bowel disease diagnostic market.
More Trending Reports by Transparency Market Research –
Remote Patient Monitoring Devices Market: https://www.prnewswire.com/news-releases/increasing-prevalence-of-chronic-diseases-set-to-propel-growth-in-remote-patient-monitoring-devices-market-tmr-301147579.html
Assisted Reproductive Technology Market: https://www.biospace.com/article/assisted-reproductive-technology-market-rising-demand-for-fertility-clinics-aids-growth-of-market/
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453